Davidson Michael H.'s Form 4 filing
NewAmsterdam Pharma Co N.V. (NAMS) · filed Mar 2, 2026
- Accession no.
- 0001193125-26-085947
- Filed
- Mar 2, 2026
- Trade date
- Mar 2, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $14.8M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Davidson Michael H.CIK 0001573785 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Ordinary Shares | MOption exerciseAcquired | +443,707 | –F1 | – | 617,851 | Direct | |
| Mar 2, 2026 | Ordinary Shares | SSaleDisposed | −443,707 | $33.25 | −$14,753,257.75 | 174,144 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Ordinary Shares | MOption exerciseDisposed | −443,707 | $0.00 | $0 | 239,267 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The exercise price of the option is EUR 1.16392.
Referenced by the price of 1 transaction in Table I.